Siga Technologie Stock Price, News & Analysis

SIGA Technologies, Inc. (SIGA) has initiated a clinical program to expand the FDA label for TPOXX® to include Post-Exposure Prophylaxis (PEP) for smallpox. The first study will compare immune responses to the Jynneos vaccine in participants receiving TPOXX. A second study aims to develop a safety dataset for extending TPOXX's dosing from 14 to 28 days. The research is supported by a $26 million R&D contract with the U.S. Department of Defense, highlighting concerns about smallpox as a potential bioweapon. TPOXX was previously approved for treating smallpox in July 2018.

SIGA Technologies, Inc. (SIGA) will host a webcast and conference call to provide a business update on March 3, 2022, at 4:30 PM ET. Participating will be CEO Dr. Phil Gomez and CFO Daniel Luckshire. The call can be accessed via a dedicated phone line or through a live webcast available on the company’s website. SIGA focuses on the health security market, with its lead product TPOXX® approved for treating human smallpox and various pox diseases. The company highlights the importance of TPOXX in biodefense and preparedness.

SIGA Technologies has announced a collaboration with Bioarchitech to investigate the use of TPOXX® (tecovirimat) combined with Bioarchitech's oncolytic vaccinia immunotherapy platform. This partnership aims to enhance the efficacy of cancer treatments by utilizing TPOXX to allow for higher doses of vaccinia vectors, potentially improving patient outcomes. TPOXX has FDA approval for smallpox treatment and has shown effectiveness against various orthopoxviruses. This collaboration reflects SIGA's commitment to advancing health security through innovative therapies.

SIGA Technologies (SIGA) announced its participation in the Edison Group’s Global Healthcare Open House Conference on January 25-27, 2022. CEO Phil Gomez will present and be available for 1x1 meetings. The company presentation will be available on demand starting January 26 at 7am ET on edison.com. This follows SIGA's recent FDA and EMA approvals for its lead product, TPOXX, an antiviral for smallpox and related diseases. For registration details, visit SIGA's investor page.

SIGA Technologies, Inc. (SIGA) has received European Medicines Agency (EMA) approval for oral tecovirimat, the same formulation previously approved by the U.S. FDA. The approval allows SIGA to market tecovirimat for treating smallpox, monkeypox, cowpox, and vaccinia complications in the EU, Norway, Iceland, and Liechtenstein. This regulatory milestone supports SIGA's commitment to health security and preparedness against biological threats. The company aims to enhance global access to this critical antiviral medication while maintaining its intellectual property rights.

SIGA Technologies, Inc. (SIGA) announced that Health Canada has approved oral TPOXX® (tecovirimat) for treating human smallpox in adults and children over 13 kg. This approval marks a significant milestone, facilitated by support from the Canadian Department of National Defence, ensuring the continued supply for stockpiling as a key countermeasure. SIGA's TPOXX is a vital antiviral drug that was previously FDA-approved in July 2018. The partnership with Meridian Medical Technologies will promote international sales of TPOXX outside the U.S.

SIGA Technologies, Inc. (SIGA) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) supports the Marketing Authorisation Application for oral tecovirimat, which treats smallpox and related diseases. This recommendation facilitates potential sales across EU member states, Norway, Iceland, and Liechtenstein, with SIGA targeting EMA approval by Q1 2022. SIGA's strategy aims to enhance global access to tecovirimat amid rising infectious disease threats, reflecting its commitment to health security.

SIGA Technologies, Inc. (SIGA) reported financial results for the third quarter of 2021, showing total revenues of $4.8 million, a significant improvement from a net loss of $3.1 million in Q3 2020. For the first nine months, revenues reached $18.3 million, compared to $87.2 million for the same period in 2020. The company is set to deliver approximately $113 million of oral TPOXX® to the U.S. government in Q4 2021. SIGA has repurchased about 1.1 million shares for $7.1 million in Q3 2021, totaling approximately $49 million in its current repurchase program.

SIGA Technologies (NASDAQ: SIGA) announced a conference call on November 4, 2021, at 4:30 P.M. ET, to provide a business update. The call will include CEO Dr. Phil Gomez and CFO Daniel Luckshire, and will be accessible via phone or live webcast. SIGA focuses on health security, primarily through its lead product, TPOXX® (tecovirimat), an antiviral for smallpox treatment, with approximate government orders of $705 million for preparedness. The company emphasizes its role in biodefense and emerging infectious diseases.